Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2012-12-21

FDA Approved: AMPYRA — Supplemental Application (Merz Pharmaceuticals, LLC)

View source ↗

Summary

The FDA approved a supplemental application for AMPYRA (dalfampridine) filed by Merz Pharmaceuticals, LLC. This action updates the regulatory status of AMPYRA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ampyra (4-aminopyridine)

Snippet

SUPPL AP for AMPYRA (DALFAMPRIDINE)